CATX Perspective Therapeutics, Inc.
Pharmaceutical Preparations · NYSE · SEC CIK 728387 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-16.2%
TTM EPS YoY16.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-45.8%
ROA-37.2%
ROIC (approx.)-44.1%
Asset turnover—
Leverage & solvency
Liabilities / assets19.4%
Debt / equity0.01x
Current ratio5.18x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.88x
Accruals ratio-4.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20232022-12-31 | FY20222022-06-30 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | $1.43M | $0 | $10.79M |
| Cost of revenue | — | — | — | — | $6.18M |
| Gross profit | — | — | $1.43M | $0 | $0 |
| R&D expense | $84.22M | $41.64M | $21.31M | $881,000 | $850,000 |
| SG&A expense | $30.23M | $26.61M | $21.06M | $7.49M | $5.57M |
| Operating income | -$113.56M | -$90.89M | -$40.94M | -$8.67M | -$6.42M |
| Interest expense | — | — | $84,000 | $0 | $0 |
| Pretax income | -$104.43M | -$80.43M | -$40.11M | -$8.05M | -$6.30M |
| Income tax | -$793,000 | -$2.10M | -$2.65M | $0 | $0 |
| Net income | -$103.12M | -$79.28M | -$46.51M | -$10.76M | -$7.27M |
| EBITDA | -$110.31M | -$88.58M | -$39.95M | -$8.40M | -$6.17M |
| EPS (basic) | -1.40 | -1.23 | -1.74 | -0.08 | -0.05 |
| EPS (diluted) | -1.40 | -1.23 | -1.74 | — | — |
| Weighted avg. shares (diluted) | 73.81M | 64.42M | 26.76M | — | — |
| Balance sheet | |||||
| Cash & equivalents | $30.63M | $61.58M | $9.24M | $20.99M | $55.89M |
| Short-term investments | $114.11M | $165.34M | $0 | $22.76M | $0 |
| Receivables | $6,000 | $116,000 | $1.17M | $1.36M | $1.61M |
| Inventory | — | — | — | $1.41M | $1.40M |
| Current assets | $148.39M | $231.16M | $16.84M | $53.22M | $59.33M |
| PP&E, net | $76.60M | $57.32M | $5.58M | $371,000 | $1.98M |
| Goodwill | — | $0 | $24.06M | $0 | — |
| Intangibles | $362,000 | $279,000 | $354,000 | $25,000 | $107,000 |
| Total assets | $266.97M | $341.10M | $97.89M | $58.09M | $64.44M |
| Current liabilities | $28.68M | $18.23M | $15.66M | $3.12M | $2.27M |
| Long-term debt | $1.62M | $1.68M | $1.73M | — | — |
| Total debt | $1.62M | $1.68M | $1.73M | — | — |
| Total liabilities | $59.94M | $50.43M | $22.71M | $3.45M | $3.16M |
| Shareholders' equity | $207.03M | $290.67M | $75.18M | $54.64M | $61.28M |
| Net debt | -$29.00M | -$59.90M | -$7.51M | — | — |
| Shares outstanding | 74.34M | 70.67M | 28.18M | 142.11M | 142.04M |
| Cash flow statement | |||||
| Operating cash flow | -$82.48M | -$18.29M | -$36.91M | -$10.40M | -$7.71M |
| Capital expenditure | $12.75M | $54.41M | $1.07M | $282,000 | $266,000 |
| Free cash flow | -$95.23M | -$72.71M | -$37.98M | -$10.68M | -$7.98M |
| Investing cash flow | $41.23M | -$218.93M | $24.37M | -$28.99M | -$284,000 |
| Financing cash flow | $10.30M | $289.38M | $785,000 | $28,000 | $56,000 |
| Depreciation & amortization | $3.25M | $2.31M | $986,000 | $267,000 | $248,000 |
| Stock-based compensation | $8.97M | $5.39M | $3.74M | $983,000 | $1.09M |
Free plan shows the latest 5 periods; Pro shows all 16 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.